quinazolines has been researched along with azd3759 in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 10 (71.43) | 24.3611 |
2020's | 4 (28.57) | 2.80 |
Authors | Studies |
---|---|
Chen, K; Cheng, Z; Johnström, P; Li, DY; Varnäs, K; Wang, J; Yang, ZF; Zeng, Q; Zhang, X | 1 |
Afzelius, L; Ahlgren, C; Farde, L; Gruber, S; Halldin, C; Jerning, E; Johnström, P; Juréus, A; Malmborg, J; Schött, P; Schou, M; Varnäs, K | 1 |
Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X | 1 |
Deng, Z; Mu, Y; Sun, P; Xiong, S; Xue, M; Zhou, R | 1 |
Planchard, D | 1 |
Ahn, JS; Ahn, MJ; Cho, BC; Goldman, JW; Harrop, B; John, T; Kao, S; Kim, DW; Kim, HR; Kim, SW; Kim, TM; Lee, JS; Lin, CC; Natale, R; Overend, P; Rabbie, S; Su, WC; Yang, JC; Yang, Z | 1 |
Li, X; Wang, J; Wang, Y; Xing, L; Yang, Z; Yu, J; Zhang, T; Zheng, L | 1 |
Aarons, L; Martin, EC; Yates, JWT | 1 |
Chao, D; Liu, K; Pang, L; Shi, Y; Wang, W | 1 |
Chen, K; Colclough, N; Fridén, M; Johnström, P; McGinnity, DF | 1 |
Cai, E; Del Cid Pellitero, E; Durcan, TM; Fon, EA; Larroquette, F; Luo, W; Soubannier, V; Tavassoly, O; Thomas, RA | 1 |
Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R | 2 |
Liang, Y; Meng, F; Qiao, Z; Zhi, S | 1 |
1 trial(s) available for quinazolines and azd3759
Article | Year |
---|---|
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Piperazines; Quinazolines; Republic of Korea; Taiwan; Treatment Outcome; United States | 2017 |
13 other study(ies) available for quinazolines and azd3759
Article | Year |
---|---|
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Topics: Animals; Brain; Brain Neoplasms; Central Nervous System; Clinical Trials, Phase I as Topic; Dogs; Drug Discovery; ErbB Receptors; Macaca fascicularis; Male; Mice; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Xenograft Model Antitumor Assays | 2015 |
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.
Topics: Animals; Benzofurans; Blood Proteins; Brain; Humans; Macaca fascicularis; Memory; Mice; Piperazines; Positron-Emission Tomography; Psychotropic Drugs; Quinazolines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Antagonists | 2016 |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord | 2016 |
Determination of AZD3759 in rat plasma and brain tissue by LC-MS/MS and its application in pharmacokinetic and brain distribution studies.
Topics: Animals; Brain; Chromatography, Liquid; Piperazines; Quinazolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2017 |
AZD3759 for CNS metastases in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
Topics: Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; DNA Repair; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Quinazolines; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays | 2018 |
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Luminescent Measurements; Lung Neoplasms; Mice; Neoplasm Staging; Piperazines; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Piperazines; Quinazolines; Signal Transduction; Smad4 Protein; Tumor Suppressor Protein p53 | 2019 |
Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Drug Discovery; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2019 |
Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation.
Topics: alpha-Synuclein; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Male; Mice; Mice, Inbred C57BL; Piperazines; Quinazolines; RNA, Small Interfering; Synucleinopathies | 2021 |
AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Janus Kinases; Male; Mice; Piperazines; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
Topics: Acrylamides; Aniline Compounds; Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Quinazolines; Xenograft Model Antitumor Assays | 2022 |
Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer.
Topics: Central Nervous System; Dimyristoylphosphatidylcholine; Lipid Bilayers; Molecular Dynamics Simulation; Piperazines; Quinazolines | 2022 |